Transthyretin-targeting therapies are effective for managing ATTR-CM
Drugs that target the transthyretin protein have life-extending potential for patients with ATTR-CM and are safe to use.
News
-
-
New review explores benefits from recent advances in ATTR-CM treatment options
Tafamidis and acoramidis reduce mortality and improve quality of life for many patients living with ATTR-CM.
-
Study examines arrhythmias in ATTR-CM, a frequent complication
Arrhythmias appear to be a common complication in patients with ATTR-CM and may contribute to an increased risk of mortality.
-
Age, left atrium size associated with atrial fibrillation in ATTR-CM
In a recent study, left atrial dilation and advanced age were identified as predictors of atrial fibrillation in patients with ATTR-CM.
-
Artery dysfunction in ATTR-CM: An underestimated component?
Abnormalities in the function of arteries and small blood vessels represent a key component of ATTR-CM pathology and a therapeutic target.
-
Case report shows amyloid can build up in the heart’s right atrium in ATTR-CM
A recent case report showed that transthyretin amyloid cardiomyopathy (ATTR-CM) may not always follow the same rules in every patient.
-
Study calls attention to under-recognized cases of dual amyloidosis
A recent case study describes the dual occurrence of Alzheimer’s disease and ATTRwt, the most common form of ATTR-CM.
-
Patients with ATTR-CM are being diagnosed and treated earlier, but challenges remain
In the last decade, better awareness, improved diagnostic tools and new treatments have helped doctors diagnose ATTR-CM earlier on.
-
Early spinal surgery may indicate future ATTR-CM
Sixteen percent of patients developed transthyretin amyloid cardiomyopathy (ATTR-CM) within six years of surgery for lumbar spinal stenosis.
-
Current and future insights in ATTR-CM management
A recently published review summarized the advances in ATTR-CM screening, diagnosis and treatment and analyzed future perspectives.
